TABLE 2.

Pharmacokinetics of rifampin

GroupMean (95% CI)
Cmaxa (μg/ml)Tmaxb (h)AUC0-8c (μg/ml · h)AUC0-∞c (μg/ml · h)Cld (ml/min)t1/2e (h)
Pulmonary TB (n = 13)7.2 (5.5-8.9)2.4 (1.7-3.1)33.0 (26.7-39.4)44.6 (36.3-52.9)15.0 (11.8-18.2)3.0 (2.1-3.9)
HIV (n = 13)3.4f (2.5-4.3)3.9 (2.7-5.0)14.1f (9.9-18.2)21.2f (14.8-27.6)35.8f (27.3-44.2)3.2 (2.6-3.7)
HIV-TB (n = 15)3.4f (2.7-4.2)3.6 (2.7-4.5)16.5f (12.4-20.6)28.2f (18.1-38.4)37.3f (21.4-53.2)2.6 (1.7-3.5)
  • a C max, peak concentration.

  • b Tmax, time to attain Cmax.

  • c AUC, area under the plasma concentration versus time curve.

  • d Cl, clearance.

  • e t 1/2, elimination half-life.

  • f P < 0.05 (versus pulmonary TB results).